Forecasting the Annual Incidence of TB in Namibia Using the Multilayer Perceptron

Dr. Smartson. P. NYONIZICHIRe Project, University of Zimbabwe, Harare, ZimbabweThabani NYONIDepartment of Economics, University of Zimbabwe, Harare, Zimbabwe

Vol 5 No 3 (2021): Volume 5, Issue 3, March 2021 | Pages: 321-325

International Research Journal of Innovations in Engineering and Technology

OPEN ACCESS | Research Article | Published Date: 01-04-2021

doi Logo doi.org/10.47001/IRJIET/2021.503055

Abstract

Namibia is a high TB burden and high TB incidence country in the SADC region. The government is working very hard in the prevention and control of TB because it has experienced a downward trend in the incidence of TB between 2000-2018 through implementation of effective preventive and control measures. In this research article, the ANN approach was applied to analyze TB incidence in Namibia. The employed data covers the period 2000-2018 and the out-of-sample period ranges over the period 2019-2023. The residuals and forecast evaluation criteria (Error, MSE and MAE) of the applied model indicate that the model is stable in forecasting TB incidence Namibia. The results of the study indicate that the country will continue to experience a downward trajectory in the incidence of TB over the period 2019-2023. Amongst other strategies the government of Namibia should intensify TB surveillance and control strategies to significantly reduce TB incidence to below 30 new cases per 100 000 population/year.

Keywords

ANN, Forecasting, TB incidence.


Citation of this Article

Dr. Smartson. P. NYONI, Thabani NYONI, “Forecasting the Annual Incidence of TB in Namibia Using the Multilayer Perceptron” Published in International Research Journal of Innovations in Engineering and Technology - IRJIET, Volume 5, Issue 3, pp 321-325, March 2021. Article DOI https://doi.org/10.47001/IRJIET/2021.503055

References
  1. Caminero JA (2003). A tuberculosis guide for specialist physicians. International Union Against Tuberculosis and Lung Diseases: 24.
  2. Faustini A., Hall A J & Perucci C A (2005). Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J; 26: 503–510.
  3. Hung C L., Chien J Y & Ou C Y (2015). Associated factors for tuberculosis recurrence in Taiwan: a nationwide nested case control study from 1998 to 2010. PLOS ONE
  4. Jones CL (2015). HHS public access. Department of Health and Human Services Unites States of America; 33: 395–401.
  5. Lawn L., Myer L., & Bekker LG (2006). Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS; 20: 1605–1612.
  6. Lew P., Pai M &Oxlade O (2008). Initial drug resistance and tuberculosis outcomes: systematic review and meta-analysis. Ann Intern Med; 149: 123–134.
  7. Namibia (2006) Ministry of Health and Social Services. National Guidelines for the Management of TB, 2nd edition.
  8. Namibia (2015). Republic of Namibia Ministry of Health and Social Services National Tuberculosis and Leprosy Programme Annual Report: 2014–2015. Windhoek Namibia, MoHSS.
  9. Raviglione M C & Uplekar M W (2006). WHO’s new STOP TB Strategy. Lancet 2006; 367: 952–955.
  10. Sesay M L (2017). Patient characteristics and treatment outcomes among tuberculosis patients in Sierra Leone. Minneapolis, MN, USA: Walden University.
  11. van Gorkom J, Mavhunga F, Omer O A, et al. TB control in Namibia 2002–2011: progress and technical assistance. Open Infect Dis J 2013; 7 (Suppl 1): 23–29.
  12. WHO (2006). The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/STB/2006.37. Geneva, Switzerland.
  13. WHO (2016). Global Tuberculosis Report 2016. Geneva, WHO, 2016.
  14. WHO (2019). Global Tuberculosis Report. Geneva: World Health Organization. Licence: CCBY-NC-SA3.0IGO.
  15. Wright C M., Westerkamp L., Korver S & Dobler C C (2015) Community-based directly observed therapy (DOT) versus clinic DOT for tuberculosis: a systematic review and meta- analysis of comparative effectiveness. BMC Infect Dis ;15: 210.